Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.3%

2 terminated out of 61 trials

Success Rate

94.4%

+7.9% vs benchmark

Late-Stage Pipeline

11%

7 trials in Phase 3/4

Results Transparency

6%

2 of 34 completed with results

Key Signals

2 with results94% success

Data Visualizations

Phase Distribution

44Total
Not Applicable (8)
P 1 (15)
P 2 (14)
P 3 (4)
P 4 (3)

Trial Status

Completed34
Unknown18
Recruiting4
Active Not Recruiting2
Terminated2
Withdrawn1

Trial Success Rate

94.4%

Benchmark: 86.5%

Based on 34 completed trials

Clinical Trials (61)

Showing 20 of 20 trials
NCT06950177Phase 1Active Not Recruiting

Pancoronavirus Vaccine Study in Healthy Adults

NCT04760704CompletedPrimary

Covid-19 Vaccine Response in Elderly Subjects

NCT05869968Recruiting

SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI

NCT04915820Not ApplicableCompleted

Iron and COVID-19 Vaccine Response

NCT06821100Phase 1Recruiting

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

NCT05293223Phase 2CompletedPrimary

Phase IIB Study of Recombinant Novel Coronavirus Vaccine

NCT05004740CompletedPrimary

Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1c

NCT05822219Not ApplicableActive Not Recruiting

Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases

NCT05188469Phase 1CompletedPrimary

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

NCT04830800Phase 1Completed

A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

NCT05553743Recruiting

Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health

NCT05998824Not ApplicableCompleted

COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease

NCT06597370CompletedPrimary

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population

NCT05463419Phase 2CompletedPrimary

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.

NCT04963790Not ApplicableTerminated

Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake

NCT05079633Phase 4CompletedPrimary

A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults

NCT04898946CompletedPrimary

Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

NCT05268679Completed

Covid-19 Vaccine Response in Heart Transplant Recipients

NCT06167915Phase 1Unknown

Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine (CHO Cell)LYB002V14 in Booster Vaccination

NCT05656508Phase 1CompletedPrimary

ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

Scroll to load more

Research Network

Activity Timeline